ESR1 and neoplasm: Similar oncogenic effects are observed in prostate, ovarian, lung, colon, and liver cancers, where ERα activation enhances tumor growth, migration, and the epithelial-mesenchymal transition (EMT) process, and resistance to apoptosis [32,33].